Mural Oncology
Mural Oncology
MURA
NASDAQ
3.32
USD
-12.40%
About
Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies.
The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells.
The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 72.9K |
| Three Month Average Volume | 3.7M |
| High Low | |
| Fifty-Two Week High | 17 USD |
| Fifty-Two Week Low | 2.88 USD |
| Fifty-Two Week High Date | 16 Nov 2023 |
| Fifty-Two Week Low Date | 05 Jul 2024 |
| Price and Volume | |
| Current Price | 3.32 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.01% |
| Thirteen Week Relative Price Change | -7.68% |
| Twenty-Six Week Relative Price Change | -43.98% |
| Fifty-Two Week Relative Price Change | -99,999.99% |
| Year-to-Date Relative Price Change | -52.64% |
| Price Change | |
| One Day Price Change | 1.84% |
| Thirteen Week Price Change | -1.19% |
| Twenty-Six Week Price Change | -38.40% |
| Five Day Price Change | -4.05% |
| Fifty-Two Week Price Change | -99,999.99% |
| Year-to-Date Price Change | -43.92% |
| Month-to-Date Price Change | -6.48% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 15.80714 USD |
| Book Value Per Share (Most Recent Quarter) | 12.08552 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 15.80714 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 12.08552 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -10.13431 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -12.42961 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -10.34565 USD |
| Normalized (Last Fiscal Year) | -12.42961 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -12.42961 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -10.34565 USD |
| Including Extraordinary Items (Last Fiscal Year) | -12.42961 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -10.34565 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 16.22865 USD |
| Cash Per Share (Most Recent Quarter) | 12.09326 USD |
| Cash Flow Per Share (Last Fiscal Year) | -12.27581 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -10.14391 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -9.67492 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 37.96% |
| EPS Change (Trailing Twelve Months) | 11.85% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -204,704,000 |
| Net Debt (Last Fiscal Year) | -270,852,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 10 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -197,701,000 |
| Free Cash Flow (Trailing Twelve Months) | -162,292,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -123.67% |
| Return on Assets (Trailing Twelve Months) | -131.01% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -171.33% |
| Return on Equity (Trailing Twelve Months) | -178.34% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -156.61% |
| Return on Investment (Trailing Twelve Months) | -164.28% |
| Return on Investment (5 Year) | -99,999.99% |